{"denoms":[{"counts":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"21"},{"groupId":"BG003","value":"56"}],"units":"Participants"}],"groups":[{"description":"High risk, transplant non-eligible \\[TNE\\], newly diagnosed multiple myeloma (NDMM) participants who were administered • Intravenous (IV) durvalumab at 1500 mg on Day 1 of each 28-day cycle • Oral lenalidomide (LEN) 25 mg/day (adjust per the creatinine clearance \\[CrCl\\] value) on Days 1 to 21 of each 28-day treatment cycle • Oral dexamethasone (dex) 40 mg/day (≤ 75 years old) or 20 mg/day (\\> 75 years old) on Days 1, 8, 15, and 22 of each 28-day cycle.","id":"BG000","title":"Cohort A: High Risk, TNE"},{"description":"\\>= 65 years old, transplant non-eligible \\[TNE\\], newly diagnosed multiple myeloma (NDMM) participants who were not high risk were administered • Intravenous (IV) durvalumab at 1500 mg on Day 1 of each 28-day cycle • Oral lenalidomide (LEN) 25 mg/day (adjust per the creatinine clearance \\[CrCl\\] value) on Days 1 to 21 of each 28-day treatment cycle • Oral dexamethasone (dex) 40 mg/day (≤ 75 years old) or 20 mg/day (\\> 75 years old) on Days 1, 8, 15, and 22 of each 28-day cycle, up to 12 cycles.","id":"BG001","title":"Cohort B: >=65 Years Old, TNE"},{"description":"High risk, post-transplant NDMM participants were administered the following as maintenance therapy: • Intravenous (IV) durvalumab at 1500 mg on Day 1 of each 28-day cycle • Oral lenalidomide (LEN) 10 mg/day on Days 1 to 21 of each 28-day treatment cycle.","id":"BG002","title":"Cohort C: High Risk, Post-transplant"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"4.17","value":"75.4"},{"groupId":"BG001","spread":"5.25","value":"72.5"},{"groupId":"BG002","spread":"7.52","value":"59.6"},{"groupId":"BG003","spread":"9.33","value":"68.98"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"21"},{"groupId":"BG003","value":"56"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"17"},{"groupId":"BG003","value":"17"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"21"},{"groupId":"BG003","value":"56"}],"units":"Participants"}],"title":"<=65 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"39"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"21"},{"groupId":"BG003","value":"56"}],"units":"Participants"}],"title":">65 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"20"},{"groupId":"BG003","value":"39"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"21"},{"groupId":"BG003","value":"56"}],"units":"Participants"}],"title":"<=75 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"17"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"21"},{"groupId":"BG003","value":"56"}],"units":"Participants"}],"title":">75 years"}],"paramType":"NUMBER","title":"Age, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"19"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"17"},{"groupId":"BG003","value":"37"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"21"},{"groupId":"BG003","value":"56"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"17"},{"groupId":"BG003","value":"47"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"6"}],"title":"Unknown or Not Reported"}],"denoms":[{"counts":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"21"},{"groupId":"BG003","value":"56"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"13"},{"groupId":"BG003","value":"25"}],"title":"0 = Fully Active"},{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"27"}],"title":"1 = Restrictive but ambulatory"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"4"}],"title":"2 = ambulatory but unable to work"}],"denoms":[{"counts":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"21"},{"groupId":"BG003","value":"56"}],"units":"Participants"}]}],"description":"ECOG performance status is used to assess how a subject's disease is progressing, and how the disease affects the daily living activities and determine appropriate treatment and prognosis. 0 = Fully Active, able to carry on all pre-disease performance without restriction; 1 = Restricted, in physically strenuous activity but ambulatory; 2 = Ambulatory and capable of all self-care; unable to carry out work activities; 3 = Capable of only limited self-care, confined to bed or chair \\>50% of waking hours; 4 = Completely Disabled, cannot carry on any self-care.","paramType":"COUNT_OF_PARTICIPANTS","title":"Eastern Cooperative Oncology Group (ECOG) Performance Status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"10"}],"title":"Stage I"},{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"19"}],"title":"Stage II"},{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"24"}],"title":"Stage III"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"3"}],"title":"Missing"}],"denoms":[{"counts":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"21"},{"groupId":"BG003","value":"56"}],"units":"Participants"}]}],"description":"Multiple myeloma has three stages, which are known as stage I, stage II and stage III. Staging in myeloma is done on the basis of the value of serum albumin and beta-2 microglobulin level. Stage I has the best prognosis and stage III the worst prognosis.","paramType":"COUNT_OF_PARTICIPANTS","title":"International Staging System (ISS) for MM at Diagnosis","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"19"}],"title":"Yes"},{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"19"},{"groupId":"BG003","value":"37"}],"title":"No"}],"denoms":[{"counts":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"21"},{"groupId":"BG003","value":"56"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"High-Risk Cytogenetic Abnormalities at Baseline","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG002","value":"21"},{"groupId":"BG003","value":"21"}],"title":"Positive"},{"measurements":[{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}],"title":"Negative"}],"denoms":[{"counts":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"21"},{"groupId":"BG003","value":"21"}],"units":"Participants"}]}],"description":"MRD status is either positive or negative. Positive was defined as more than 1 malignant cells in 10\\^5 cells as measured by the ClonoSIGHT(TM) NGS (next generation sequencing) assay of a bone marrow aspirate sample.","paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Data was collected for Cohort C only.","title":"Minimal Residual Disease (MRD) Status","unitOfMeasure":"Participants"}],"populationDescription":"Full analysis population. The Full Analysis Population (FAS) is defined as all participants who are enrolled (signed the inform consent form and meet all eligibility criteria) in the study. Participants are analyzed according to the initial cohort actually assigned."}